Biochemical parameters in the drug treatment of patients with chronic heart failure

DOI: https://doi.org/10.29296/25877305-2020-03-09
Download full text PDF
Issue: 
3
Year: 
2020

I. Mingalimova; L. Baleeva, Candidate of Medical Sciences; Z. Galeeva, Candidate of Medical Sciences; A. Galyavich, MD Kazan State Medical University

The mainstay of drug treatment in patients with chronic heart failure (CHF) is angiotensin-converting enzyme inhibitors, β-blockers, and mineral corticoid receptor antagonists, and, in edematous syndrome, diuretics. There is a drug treatment-induced change in number of biochemical blood parameters, such as plasma electrolytes, hormones, and catecholamines. The time course of biochemical blood changes induced by drug treatment in patients with CHF is important for the efficiency of the treatment and the control of its safety. The aim of the study was to investigate the impact of traditional inpatient drug treatment on a number of biochemical parameters in patients with obvious CHF.
Keywords: 
cardiology
chronic heart failure
treatment
biochemical blood parameters
natriuretic peptide

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Mareev V.Ju., Fomin I.V., Ageev F.T. i dr. Klinicheskie rekomendatsii. Hronicheskaja serdechnaja nedostatochnost' (HSN) // Serdechnaja nedostatochnost'. – 2017; 18 (1): 3–40 [Mareev V.Yu., Fomin I.V., Ageev F.T., Arutyunov G.P. et al. Clinical guidelines. Chronic heart failure (CHF) // Russian Heart Failure Journal. – 2017; 18 (1): 3–40 (in Russ.)]. DOI: 10.18087/rhfj.2017.1.2346
  2. Triposkiadis F., Karayannis G., Giamouzis G. et al. The Sympathetic Nervous System in Heart Failure. Physiology, Pathophysiology, and Clinical Implications // J. Am. Coll. Cardiol. – 2009; 54: 1747–62. DOI: 10,1016/j.jacc.2009.05.015 Lymperopoulos A., Rengo G., Koch W. Adrenergic Nervous System in Heart Failure: Pathophysiology and Therapy // Circulation Research. – 2013; 113: 739–53. DOI: 10,1161 / CIRCRESAHA.113.300308
  3. Grodin J., Verbrugge F., Ellis S. et al. Importance of Abnormal Chloride Homeostasis in Stable Chronic Heart Failure // Circ. Heart Fail. – 2016; 9: e002453. DOI: 10.1161/CIRCHEARTFAILURE.115.002453
  4. Januzzi J., Rehman S., Mohammed A. et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction // J. Am. Coll. Cardiol. – 2011; 58: 1881–9. DOI: 10,1016 / j.jacc.2011.03.072
  5. Fonarow G., Peacock W., Phillips C. et al. Admission B-type natriuretic peptide levels and inhospital mortality in acute decompensated heart failure // J. Am. Coll. Cardiol. – 2007; 49: 1943–50. DOI: 10,1016/j.jacc.2007.02.037
  6. Cleland J., McMurray J., Kjekshus J. et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure) // J. Am. Coll. Cardiol. – 2009; 54: 1850–9. DOI: 10,1016 / j.jacc.2009.06.041
  7. Sachdeva A., Horwich T., Fonarow G. Comparison of usefulness of each of five predictors of mortality and urgent transplantation in patients with advanced heart failure // Am. J. Cardiol. – 2010; 106: 830–5. DOI: 10.1016/j.amjcard.2010.04.045
  8. Troughton R., Felker G., Januzzi J. Natriuretic peptide-guided heart failure management // Eur. Heart J. – 2014; 35: 16–24. https://doi.org/10.1093/eurheartj/eht463
  9. Latini R., Masson S., Anand I. et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure // Circulation. – 2007; 116: 1242–9. DOI: 10.1161/CIRCULATIONAHA.106.655076
  10. Huelsmann M., Neuhold S., Resl M. et al. PONTIAC (NT-proBNP Selected PreventiOn of cardiac events in a population of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial // J. Am. Coll. Cardiol. – 2013; 62: 1365–72. DOI: 10,1016 / j.jacc.2013.05.069
  11. Ledwidge M., Gallagher J., Conlon C. et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial // JAMA. – 2013; 310: 66–74. DOI: 10,1001 / jama.2013.7588